In ₹ Crore except Per Share Latest Annual	SHARDACROP FY26	UPL FY26	PIIND FY26	STYRENIX FY26	Peer Average
Valuation — at last close
P/E	◆ 9.04×	24.28×	24.24×	17.42×	21.98× -59%
P/B	1.96×	◆ 1.32×	2.86×	2.33×	2.17× -10%
EV/EBITDA	◆ 5.18×	7.30×	16.95×	9.72×	11.32× -54%
Market Cap	₹6,156 Cr	₹45,795 Cr	₹32,072 Cr	₹3,187 Cr	₹27,018 Cr -77%
Growth
Revenue CAGR 3Y	9.20%	-1.09%	1.13%	◆ 13.17%	4.40% +109%
Revenue CAGR 5Y	◆ 17.07%	6.02%	7.96%	16.08%	10.02% +70%
Net Income CAGR 3Y	◆ 25.81%	-20.47%	2.42%	-0.03%	-6.03% +528%
Revenue YoY (latest Q)	13.19%	10.47%	-10.43%	◆ 24.36%	8.13% +62%
Net Income YoY (latest Q)	23.36%	◆ 58.52%	-38.95%	-48.19%	-9.54% +345%
Profitability
EBITDA Margin	20.43%	17.89%	◆ 25.32%	9.98%	17.73% +15%
Net Income Margin	12.93%	4.28%	◆ 19.67%	5.32%	9.76% +33%
Return on Common Equity	◆ 24.16%	6.01%	12.16%	14.43%	10.87% +122%
Return on Capital Employed	◆ 24.51%	10.06%	11.64%	12.97%	11.56% +112%
Return on Assets	◆ 12.96%	2.42%	10.27%	7.66%	6.78% +91%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.53×	0.02×	0.23×	0.26× -100%
Interest Coverage	◆ 427.86×	1.77×	78.84×	11.78×	30.80× +1289%
Scale — latest FY
Revenue / Total Income	₹5,268 Cr	₹51,839 Cr	₹6,714 Cr	₹3,438 Cr	₹20,664 Cr -75%
Net Income	₹681 Cr	₹2,220 Cr	₹1,321 Cr	₹183 Cr	₹1,241 Cr -45%
Total Assets	₹5,780 Cr	₹95,205 Cr	₹13,444 Cr	₹2,483 Cr	₹37,044 Cr -84%
EPS	₹75.47	₹22.32	₹87.06	₹103.98	₹71.12 +6%
Book Value per Share	₹347.65	₹410.6	₹738.85	₹776.75	₹642.07 -46%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.